Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1

This publication has 24 references indexed in Scilit:

• Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients
  HIV Research & Clinical Practice, 2004
• Interactions between Atazanavir-Ritonavir and Tenofovir in Heavily Pretreated Human Immunodeficiency Virus-Infected Patients
  Antimicrobial Agents and Chemotherapy, 2004
• Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
  Clinical Pharmacology & Therapeutics, 2004
• MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males
  British Journal of Clinical Pharmacology, 2002
• Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein
  Clinical Pharmacology & Therapeutics, 2002
• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
  The Lancet, 2002
• Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
  Proceedings of the National Academy of Sciences, 2000
• BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
  Annual Review of Pharmacology and Toxicology, 1999
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
  Journal of Clinical Investigation, 1998
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
  Proceedings of the National Academy of Sciences, 1987